- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation ; volume:38 ; number:02 ; year:1977
Konferenz: VIth International Congress on Thrombosis and Haemostasis; 1977-06-27
Thrombosis and haemostasis ; 38, Heft 02 (1977)
- Beteiligte Personen und Organisationen
-
Gjesdal, K.
- DOI
-
10.1055/s-0039-1682424
- URN
-
urn:nbn:de:101:1-2019061209293916203355
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.01.2025, 00:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gjesdal, K.
Ähnliche Objekte (12)
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides